GovChime
Notice ID: b6cd48a43cd14d84af4690e7bda74b10Combined Synopsis/Solicitation

Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response

Archived on September 14, 2021. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 PM UTC−04:00
Posted
September 10, 2021
Notice type
Combined Synopsis/Solicitation
NAICS
325414: Biological Product (except Diagnostic) Manufacturing
Agency
Department of Health and Human ServicesOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Notice details

Office
ASPR BARDA DIV CONTRACTS MGMT & ACQ
Place of performance
DC
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75A50121R00013
Notice ID
b6cd48a43cd14d84af4690e7bda74b10

Description

Reference Amendment 1 PERIOD OF PERFORMANCE a. The base period of performance of this contract is anticipated for thirty-six (36) months from date of award. The period of performance may be extended up to 24 months with the exercise of option(s), structured as CLINs. b. If the Government exercises its option(s), the period of performance will be increased as listed below: Option I Twelve (12) Months (Year 4) Option II Twelve (12) Months (Year 5) The Statement of Work (SOW) delineates the specifics of the supplies or services to be furnished. The minimum guarantee is $50,000.00 for the duration of any resultant contract (base + options). Provide firm-fixed prices for all CLINs, except those CLINs which have TBD or N/A in the Estimated Maximum Quantity column. Provide pricing based upon the CLIN, item name and description in the SOW contained in Section C for the three (3) year base period, and item name and description for the two 12-month option periods, as the numbers in SOW reflect base period numbering (SOW Numbering identified in SOW would be revised in conjunction with any resultant option award with description data unchanged). Price/Cost, e.g., Firm-fixed-price or cost reimbursable, for TBD CLINs, i.e., 0008, 0010, 0011, 0012, 0013, and 0014 will be determined as a result of the issuance of a Request for Task Order Response (RTOR) to any or all resultant contract awardee(s). C.2.1. Detailed Description of Contract Line Item Numbers (CLINs): Reference attached RFP for additional detail CLINs will differ for option periods with item name and scope unchanged. CLIN 0001: cGMP Influenza Vaccine Master and Working Seed Lot The Contractor shall provide yield optimized master and working seed lots for inactivated, live attenuated,or recombinant influenza vaccine product. CLIN 0002: Influenza Vaccine Research Lot(s) The Contractor shall provide an influenza vaccine small scale, research lot. CLIN 0003: cGMP Influenza Vaccine: Investigational Lot(s) The Contractor shall provide influenza vaccine investigational lot(s). CLIN 0004: cGMP Influenza Vaccine: Commercial Scale Bulk Lot(s) The Contractor shall provide influenza vaccine bulk product. CLIN 0005: cGMP Adjuvant: Clinical or Commercial Scale Bulk Lot(s) The contractor shall provide adjuvant bulk product suitable for formulation and fill-finishing for use in the clinic, including clinical trial or use during a public health emergency. Proposed adjuvant shall have completed Phase 2 development in combination with a pandemic influenza or pre-pandemic influenza or emerging pathogen antigen. Clinical evidence of antigen sparing and/or adjuvant benefit for the pandemic influenza or pre-pandemic influenza or emerging pathogen antigen is required. CLIN 0006: Formulation and Filling The unit for this item is each (vial, syringe and sprayer) Submit standard data report according to instructions in Reporting Requirements. Provide a final report including, at minimum, the information identified in the Final Report Requirements. CLIN 0006A: Antigen: Single dose vials CLIN 0006B: Antigen: Syringes or sprayers CLIN 0006C: Antigen: Multi-dose vials CLIN 0006D: Adjuvant: Single dose vials CLIN 0006E: Adjuvant: Multi-dose vials CLIN 0006F: Co-formulated antigen and adjuvant: Single dose vials CLIN 0006G: Co-formulated antigen and adjuvant: Syringes CLIN 0006H: Co-formulated antigen and adjuvant: Multi-dose vials CLIN 0007: Storage and Stability Submit standard data report according to instructions in Reporting Requirements. Provide a final report including, at minimum, the information identified in the Final Report Requirements CLIN 0007A: Storage and Stability of investigational lots of antigen. The unit for this item is a lot, which equals storage and stability for one (1) lot/month. CLIN 0007B: Storage and Stability of commercial scale bulk lots of antigen. The unit for this item is a lot, which equals storage and stability for one (1) lot/month. CLIN 0007C: Storage and Stability of antigen in final container. The unit for this item is a final container which equals storage and stability for a single (1) final container/month. CLIN 0007D: Storage and Stability of clinical/commercial scale lots of adjuvant. The unit for this item is a lot which equals a single (1) month of storage and stability for a single (1) lot/month. CLIN 0007E: Storage and Stability of adjuvant in final container. The unit for this item is a final container which equals storage and stability for a single (1) final container/month. CLIN 0008: Shipping CLIN 0009: Candidate Vaccine Virus (CVV) CLIN 0010: Potency reagent and standards manufacture and testing .The Contractor shall provide influenza vaccine reagents and standards. CLIN 0011: Analytical Laboratory Testing/Assay CLIN 0012: Non-Clinical Studies CLIN 0013: Clinical Studies CLIN 0014: Disposal of product CLIN 0015: Standard Data Reporting Requirements CLIN 0016: Additional Reporting CLIN 0017: Storage and Stability of Materials from Prior Contracts CLIN 0017A: Storage and Stability of commercial scale bulk lots of antigen. The unit for this item is a lot, which equals storage and stability for one (1) lot/month. CLIN 0017B: Storage and Stability of antigen in final container. The unit for this item is a final container which equals storage and stability for a single (1) final container/month. CLIN 0017C: Storage and Stability of clinical/commercial scale lots of adjuvant. The unit for this item is a lot which equals a single (1) month of storage and stability for a single (1) lot/month. CLIN 0017D: Storage and Stability of adjuvant in final container. The unit for this item is a final container which equals storage and stability for a single (1) final container/month. CLIN 0018: Emerging Pathogen. The contractor shall perform activities as required by HHS and as specified in an RTOR.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75A50121R00013
  1. Combined Synopsis
  1. 11×
    Combined SynopsisCurrentJun 29, 2021

    Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response

    Notice b6cd48a43cd14d84af4690e7bda74b10 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Annual delivery order issued on a sole-source basis from the Department of Veteran’s Affairs Glaxosmith Kline federal supply schedule for pharmaceuticals and vaccines. The specific contract number is 36F79722D0178. The delivery order will be for proprietary Fluarix and Flulaval Influenza vaccines.
-Sole Source / J&AOpen
Fluzone and Flublok Influenza Vaccines for the 2026-2027 Flu season. The vaccine is required to immunize embassy immunocompromised family members.
-Sole Source / J&AOpen
Please note this solicitation is not ready to be issued as of this date. The Embassy of the United States in the Philippines will launch the solicitation on the SAM.gov website when it is available. This solicitation is for the Supply and Delivery of Medical Supplies. All responsible sources may submit a quotation, which will be considered. The Government may award the contract based on the initial offer without discussion. The resultant contract will be a firm fixed price type contract. The Government plans to issue the solicitation on or about the third week of April 2025. The proposal due date will be set forth in the solicitation. All contractors shall be registered in the SAM (System for Award Management) Database https://sam.gov/content/home prior to submitting an offer pursuant to FAR provision 52.204-7. Therefore, prospective offerors are required to register prior to the submittal of proposals. The guidelines for registration in SAM are also available at: https://sam.gov/content/entity-registration Electronic Submission/Responses: This opportunity allows for electronic responses. Please submit your offer via email to ManilaContracting@state.gov prior to the response date and time. It is important to make sure the submission is made in specific size and format; in MS-Word 2007/2010 or MS-Excel 2007/2010 or Adobe Acrobat (pdf) file format. The file size must not exceed 10MB. If the file size should exceed the 10MB, the submission must be made in separate files and attached to separate emails with less than 10MB each.
-Pre-SolicitationOpen
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: The National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to award a Firm-Fixed-Price Purchase Order to Creative Biolab Inc. for culture all cells and differentiate them, expand their cell populations to more than 20 million, collect them, verify cell count, and send them back to us. Description of the Requirement The primary objective of this study is to sequence and analyze the 4q35 locus on Chromosome 4 for several years. This locus is a gene-poor and extremely long (>100K) region of DNA that consists of many repetitive sequences which makes sequencing and analysis extremely difficult. To sequence this locus using Nanopore Sequencing technology. To expand the number of samples for our experiment, we looked for a company that can handle numerous cell lines and follow the protocol that we provide. Creative Biolabs is the only company/research institute that has been able to perform differentiation within 3 months and has the ability to follow our protocol with numerous cell lines. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Only Creative Biolabs was willing to follow our exact protocol and had the logistical capacity to handle the large number of cell lines that we need to analyze, which is vital to research at the National Institute of Environmental Health Sciences. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 13, 2026. Please reference Notice No. 75N98027Q00053 in the subject line of the submission.
-Pre-Solicitation11/12/2026
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
-Pre-Solicitation11/11/2026

Additional Details

Solicitation Number

75A50121R00013

Archive Date

Sep 14, 2021

Office Address

Washington, DC, 20515